TRAIL (TNF-related apoptosis-inducing ligand).

Format:

Book

Contributor:

Thimann, Kenneth Vivian, 1904-1997.

Series:

Vitamins and hormones ; 67.

Vitamins and hormones ; 67

Language:

English

Subjects (All):

Vitamins.

Hormones.

Physical Description:

1 online resource (521 p.)

Place of Publication:

New York : Academic Press, 2004.

Language Note:

English

Summary:

The discovery of TRAIL (TNF Related Apoptosis Inducing Ligand), also referred to as Apo-2, is in an era of intense research because TRAIL induces many cancer cells to undergo programmed cell death (apoptosis), while having no effect on normal cells. This important protein deserves extensive review at a formative time in the devlopement of our knowledge concerning its mechanism of action and the ways in which it can be used as a cancer chemotherapeutic agent. Consequently, this voume reviews the current status of research on TRAIL.Selected Contents:* Crystal Structure of RANK Liga

Contents:

Cover; Contents; Contributors; Preface; Chapter 1. Specificity of Molecular Recognition Learned from the Crystal Structures of TRAIL and the TRAIL:sDR5 Complex; I. Introduction: The TNF and TNF Receptor Superfamilies; II. TRAIL and its Receptors; III. Selective Antitumor Activity and Biologic Functions of TRAIL; IV. Overall Structure of TRAIL; V. Zinc Binding and its Critical Role; VI. Unique Frame Insertion in the AA'' Loop; VII. Structure of TRAIL:sDR5 Complex; VIII. Determinants Conferring Specificity of Receptor Recognition; IX. Conclusions and Perspectives; References

Chapter 2. Crystal Structure of RANK Ligand Involved in Bone MetabolismI. Introduction; II. The OPG/RANKL/RANK System; III. Three-Dimensional Structure of RANKL; IV. Conclusion; References; Chapter 3. Promoter of TRAIL-R2 Gene; I. Introduction; II. Basic Structure of TRAIL-R2 Promoter; III. Regulator of TRAIL-R2; IV. Possibility of Cancer Therapy Using TRAIL-R2; References; Chapter 4. Transcriptional Regulation of the TRAIL-R3 Gene; I. Introduction: TRAIL and its Receptors; II. Decoy Receptors; III. TRAIL-R3; IV. Future Directions; References; Chapter 5. Monoclonal Antibodies Against TRAIL

I. IntroductionII. Overview of Monoclonal Antibodies Against TRAIL; III. Applications of Monoclonal Antibodies Against TRAIL; IV. Physiologic Significance of TRAIL; V. Future Aspects; References; Chapter 6. Modulation of TRAIL Signaling Complex; I. TRAIL: A New Member of TNF Family; II. TRAIL Death Receptors: DR4 and DR5; III. TRAIL Decoy Receptors. DcR1, DcR2, and OPG; IV. TRAIL-Induced DISC: Cleavage of Apoptosis Initiating Protease Caspase-8; V. TRAIL-Induced Bid Cleavage: Activation of Mitochondrial Pathways; VI. TRAIL-Induced Cell Proliferation: RIP-Mediated NF-kB Activation

V. Functions of CARDINALVI. CARDINAL as a Negative Regulator of Diverse NFkB Activation Pathways; VII. CARDINAL and Apoptosis; VIII. CARDINAL and Caspase-1 Activation; IX. The Inflammasome; X. CARDINAL Contradictions; XI. Conclusions; References; Chapter 9. TRAIL in the Airways; I. Introduction; II. TRAIL: Synthetic and Signaling Pathways; III. Effects of TRAIL in the Airways; IV. Conclusions; References; Chapter 10. TRAIL Death Receptors, Bcl-2 Protein Family, and Endoplasmic Reticulum Calcium Pool; I. Introduction; II. The Endoplasmic Reticulum

III. Endoplasmic Reticulum CA2+ Pools and Regulation of Apoptosis

Notes:

Description based upon print version of record.

Includes bibliographical references and index.

ISBN:

1-281-02120-2

9786611021207

0-08-052287-4

OCLC:

437182450